All Stories

  1. [18F]FDG PET/CT imaging of the metabolic response in advanced breast cancer patients treated with cyclin-dependent kinase 4/6 inhibitors
  2. Brain fluorodeoxyglucose PET anatomical segmentation via AI: extensive validation in the neurodegenerative spectrum
  3. Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging
  4. An AI-Based Solution for Denoising Fast-Acquisition [18F]FDG PET: Clinical Feasibility and Quantitative Assessment
  5. WRONG journal! It should be "European Journal of Nuclear Medicine and Molecular Imaging"
  6. Striatal dopamine D2-like receptors availability in obesity and its modulation by bariatric surgery: a systematic review and meta-analysis
  7. Targeted radionuclide therapy directed to the tumor phenotypes: A dosimetric approach using MC simulations
  8. An Optimized Methodology for Patient-Specific Therapeutic Activity Administration in Liver Radioembolization
  9. Patlak plot based on the first 30 minutes post-injection dynamic 18F-florbetaben positron emission tomography scan separates amyloid-β positive from negative studies
  10. Brain [18F]Fluorodeoxyglucose Metabolism Assessment under Hypothyroidism and Recombinant Human Thyroid-Stimulating Hormone in Comparison with Thyroid Hormone Replacement in Patients Submitted to Total Thyroidectomy
  11. Positron Emission Tomography–Derived Metrics Predict the Probability of Local Relapse After Oligometastasis-Directed Ablative Radiation Therapy
  12. Las relaciones de ventilación/perfusión corregidas por píxeles mejoraron la detección de defectos de perfusión no coincidentes
  13. PSMA expression in thyroid nodule
  14. 123I-FP-CIT SPECT in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease: a new quantitative analysis of autopsy confirmed cases
  15. Are lesion features reproducible between 18F-FDG PET/CT images when acquired on analog or digital PET/CT scanners?
  16. Asymptomatic COVID-19 positive patient suspected on FDG-PET/CT
  17. Negative affect and stress‐related brain metabolism in patients with metastatic breast cancer
  18. Principles and Constraints of Nonrigid Registration
  19. Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients
  20. Phenotype-Oriented Ablation of Oligometastatic Cancer with Single Dose Radiation Therapy
  21. Using 3D anthropometric data for the modelling of customised head immobilisation masks
  22. Segmentation of pathological liver tissue with Dilated Fully Convolutional Networks: A Preliminary Study
  23. Evaluation of the attenuation correction on myocardial perfusion imaging: a phantom study
  24. Voxel-Based Computational Tools Help Liver Dosimetry Calculations of Multiple (External and Internal) Radiation Therapies
  25. Gastric GIST Incidentally Detected on 68Ga-PSMA-PET/CT
  26. Comparison of the 90Y-labelled glass microspheres liver radioembolisation dosimetry with the estimated dosimetry obtained from pre-treatment 99mTc-MAA SPECT images reconstructed with and without attenuation correction
  27. Radiopharmacology and molecular imaging of PD-L1 expression in cancer
  28. Patient-specific gamma-index analysis to evaluate 99mTc-MAA as a predictor for 90Y glass microspheres liver radioembolisation dosimetry
  29. Activity estimation and biokinetic analysis of 99mTc-DMSA in renal infant patients using a gamma camera
  30. Extraction, selection and comparison of features for an effective automated computer-aided diagnosis of Parkinson’s disease based on [123I]FP-CIT SPECT images
  31. Radioembolization with 90Y-Labeled Glass Microspheres: Analytical Methods for Patient-Personalized Voxel-Based Dosimetry
  32. The Importance of SPECT Imaging Attenuation Correction During Treatment Planning for 90Y-labeled Glass Microspheres Liver Radioembolization
  33. 18F-FDG Uptake in Ischemic Colitis During Follow-up of a Patient With Lung Cancer
  34. Gamma-index and dose-volume histograms (based on voxel dosimetry) to evaluate the predictive power of 99mTc-MAA SPECT maps in comparison with post-radioembolization 90Y PET maps
  35. Nuclear Medicine in Oncology
  36. Effect of reconstruction processing methods and analysis in the quantification of brain spect studies with DaTSCAN™
  37. Optimization of activity and absorbed doses calculation to target/tumor and normal liver volumes in patients submitted to yttrium-90 radioembolization with glass microspheres
  38. Nuclear medicine training in the European Union: 2015 update
  39. The influence of number of counts in the myocardium in the determination of reproducible functional parameters in gated-SPECT studies simulated with GATE
  40. Current worldwide nuclear cardiology practices and radiation exposure: results from the 65 country IAEA Nuclear Cardiology Protocols Cross-Sectional Study (INCAPS)
  41. Predicting conversion from MCI to AD with FDG-PET brain images at different prodromal stages
  42. Analysis of gated myocardial perfusion spect images based on computational image registration
  43. Estimation of the collective ionizing dose in the Portuguese population for the years 2011 and 2012, due to nuclear medicine exams
  44. Ideas from the second UEMS conference on CME/CPD: new EU directives on a patients’ rights in cross-border healthcare and professional qualifications
  45. Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging
  46. FDG gated cardiac PET at rest and immediately after dobutamine stress
  47. Monte Carlo simulation of the basic features of the GE Millennium MG single photon emission computed tomography gamma camera
  48. The new UEMS-EACCME criteria for accreditation of live educational events (LEEs): another step forward to improve the quality of continuing medical education (CME) in Europe
  49. Phenotypes of myocardial blood perfusion related to the genetic variations of metalloproteinases 3 (MMP3) and 9 (MMP9)
  50. Texton-based diagnosis of Alzheimer's disease
  51. Image quality of myocardial perfusion-gated studies: effect of ingestion of different fat content in the reduction of extra-myocardial abdominal signal
  52. Left ventricular function influenced byMMP3gene 5A/6A polymorphism (rs3025058): a gated-SPECT study
  53. Continuing Medical Education Committee and UEMS-EACCME
  54. UEMS/EBNM endeavour – celebrations keep going!
  55. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT
  56. 3D brain image-based diagnosis of Alzheimer's disease: Bringing medical vision into feature selection
  57. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?
  58. Syllabus for Postgraduate Specialization in Nuclear Medicine – 2011/2012 Update
  59. UEMS/EBNM endeavour
  60. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: A 3‐year European multicenter study with repeat [123I]FP‐CIT SPECT
  61. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy
  62. [123I] FP‐CIT spect study in vascular parkinsonism and Parkinson's disease
  63. Applications of PET–CT in clinical practice: Present and future
  64. Diagnosis and management of dementia with Lewy bodies: Third report of the DLB consortium
  65. Clinical evaluation of 2D versus 3D whole-body PET image quality using a dedicated BGO PET scanner
  66. Parkinsonism due to Kernohan notch: Clinical, structural, and functional imaging correlates
  67. Assessment of recurrent colorectal cancer following 5-fluorouracil chemotherapy using both 18 FDG and 18 FLT PET
  68. L‐dopa–responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings
  69. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease
  70. Clinical audit in nuclear medicine
  71. Comparison of methodologies for the in vivo assessment of 18 FLT utilisation in colorectal cancer
  72. Dopamine transporter binding in Gilles de la Tourette syndrome: a [123I]FP‐CIT/SPECT study
  73. Frontal lobe dysfunction in sporadic hyperekplexia
  74. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography
  75. Dementia with Lewy bodies versus Alzheimer's disease: Role of dopamine transporter imaging
  76. Corrections
  77. Potential impact of [ 18 F]3'-deoxy-3'-fluorothymidine versus [ 18 F]fluoro-2-deoxy-d-glucose in positron emission tomography for colorectal cancer
  78. Positron emission and computed X-ray tomography: a coming together
  79. [123I]‐FP‐CIT‐SPECT demonstrates dopaminergic deficit in orthostatic tremor
  80. In vivo Dopamine Pre-Synaptic Receptors and Antioxidant Activities in Patients with Alzheimer’s Disease, Dementia with Lewy Bodies and in Controls
  81. [ 123 I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia
  82. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET
  83. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study
  84. Fluorodeoxyglucose positron emission tomography in clinical oncology: the referrerʼs perspective
  85. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand
  86. Nuclear Medicine in Primary Breast Cancer Imaging
  87. Typical antipsychotic drugs — D2 receptor occupancy and depressive symptoms in schizophrenia
  88. Can ROI methodology/normalised tissue activities be used instead of absolute blood flow measurements in the brain?
  89. Glucose Utilisation and Cell Proliferation in Colorectal Cancer
  90. Dopamine neurotransmission, Parkinson’s disease and SPET
  91. The role of [18F]fluoro-2-deoxyglucose-PET scanning in the diagnosis of paraneoplastic neurological disorders
  92. The impact of FDG-PET on the management algorithm for recurrent colorectal cancer
  93. Influence of OSEM and segmented attenuation correction in the calculation of standardised uptake values for [18F]FDG PET
  94. PET e SPECT em neurologia e psiquiatria: do básico às aplicações clínicas
  95. Functional imaging of malignant paragangliomas and carcinoid tumours
  96. Clinical role of positron emission tomography in oncology
  97. Functional imaging as an aid to decision-making in metastatic paraganglioma
  98. Asymptomatic patient with an increasing concentration of CEA
  99. Positron emission tomography and colorectal cancer
  100. SPECT imaging of the dopamine transporter in juvenile-onset dystonia
  101. A SPECT study of the effect of vagal nerve stimulation on thalamic activity in patients with epilepsy
  102. Levels of γ‐Aminobutyric Acid‐Benzodiazepine Receptors in Abstinent, Alcohol‐Dependent Women: Preliminary Findings From an 123I‐Iomazenil Single Photon Emission Tomography Study
  103. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: The [123I]-FP-CIT study group
  104. Patterns of brain activity in patients with epilepsy and depression
  105. Nuclear medicine in neurology and psychiatry
  106. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies
  107. Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine
  108. Crisis after angiography: time for MIBG
  109. 5-HT2A receptor blockade in patients with schizophrenia treated with risperidone or clozapine
  110. Early detection of melanoma metastases with radioiodinated methylene blue
  111. Magnetic resonance imaging, thallium-201 SPET scanning, and laboratory analyses for discrimination of cerebral lymphoma and toxoplasmosis in AIDS.
  112. Reduced levels of GABA-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy
  113. Cognitive functioning and GABAA/benzodiazepine receptor binding in schizophrenia: A 1231-iomazenil SPET study
  114. Recurrent follicular carcinoma-oxyphilic cell type (Hürthle cell carcinoma) of the thyroid, imaging with iodine-131 and technetium-99m tetrofosmin before and after radiotherapy.
  115. Relationship Between SPECT Scans and Buspirone Tests in Patients with ME/CFS
  116. Wisconsin Card Sorting Task (WCST) errors and cerebral blood flow in obsessive‐compulsive disorder (OCD)
  117. Brain blood flow in anxiety disorders
  118. Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole
  119. Limbic selectivity of clozapine
  120. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography
  121. Dementia with Lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon mission tomography
  122. Initial evaluation of123I-5-I-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects
  123. HMPAO SPET does not distinguish obsessive–compulsive and tic syndromes in families multiply affected with Gilles de la Tourette's syndrome
  124. Psychiatric profiles and patterns of cerebral blood flow in focal epilepsy: interactions between depression, obsessionality, and perfusion related to the laterality of the epilepsy.
  125. Thrombosis and restenosis after peripheral angioplasty: Does acute 111indium-platelet accumulation predict angioplasty outcome?
  126. In vivo effects on striatal dopamine D 2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123 I IBZM single photon emission tomography (SPET) study
  127. Caudate regional cerebral blood flow in obsessive-compulsive disorder, panic disorder and healthy controls on single photon emission computerised tomography
  128. Initial evaluation of123|-5-|-R91150, a selective 5-HT2A ligand for single-photon emission tomography, in healthy human subjects
  129. Multivariate cluster analysis of dynamic iodine-123 iodobenzamide SPET dopamine D2 receptor images in schizophrenia
  130. 5-HT2A receptor blockade in vivo in schizophrenic patients treated with atypical antipsychotics: Single photon emission tomography (SPET) findings
  131. Multivariate cluster analysis of dynamic [I-123]-IBZM spet dopamine D2 receptor images in schizophrenia
  132. Non-invasive measurement of left ventricular volumes and function by gated positron emission tomography
  133. Radioiodinated methylene blue for diagnosing early melanoma metastases
  134. HMPAO SPECT in non-epileptic seizures: preliminary results
  135. The significance of increased 111indium platelet accumulation at post-angioplasty sites
  136. Polycythaemia and agoraphobia
  137. Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine — a123 IBZM single photon emission tomography (SPET) study
  138. Pathophysiology of Chronic Left Ventricular Dysfunction
  139. Baseline Left Ventricular (LV) performance and functional recovery after revascularisation: Predictive value of absolute 18F Fluorodeoxyglucose (FDG) uptake
  140. Targeting Disseminated Melanoma with Radiolabelled Methylene Blue: Comparative bio-distribution studies in man and animals
  141. Brainstem perfusion is impaired in chronic fatigue syndrome
  142. Regional Cerebral Blood Flow in Obsessive-Compulsive Disordered Patients at Rest
  143. Schizophrenic auditory hallucinations are associated with increased regional cerebral blood flow during verbal memory activation in a study using single photon emission computed tomography
  144. Immunoscintigraphy with a 99Tcm-labelled anti-granulcyte monoclonal antibody in patients with human immunodeficiency virus infection and AIDS
  145. Brain Perfusion Abnormalities in Gilles de la Tourette's Syndrome
  146. Technetium-99m-L,L-ethylenedicysteine scintigraphy in patients with renal disorders
  147. Optimised interictal HMPAO-SPECT in the evaluation of partial epilepsies
  148. Clinical brain radionuclide imaging studies
  149. Patterns of regional cerebral blood flow in corticobasal degeneration studied using HMPAO SPECT; comparison with Parkinson's disease and normal controls
  150. Differentiation between Alzheimer's disease and multi‐infarct dementia: Spect vs MR imaging
  151. Dopamine D2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride — an123I-IBZM single photon emission tomography (SPET) study
  152. In vivo imaging of GABAA receptors using sequential whole-volume iodine-123 iomazenil single-photon emission tomography
  153. Dopamine receptor availability in Tourette's Syndrome
  154. Dopamine receptor availability in Tourette's syndrome
  155. Recognition of Mental State Terms
  156. Clinical experience with a multidetector SPET system (Toshiba GCA-9300A)
  157. Chronic fatigue syndrome Role of psychological factors overemphasised
  158. Stereotypy, schizophrenia and dopamine D2 receptor binding in the basal ganglia
  159. Regional cerebral blood flow (rCBF) in schizophrenia during verbal memory activation: a 99mTc-HMPAO single photon emission tomography (SPET) study
  160. Striatal dopamine receptor binding in epileptic psychoses
  161. HMPAO SPECT in Parkinson's disease before and after levodopa: correlation with dopaminergic responsiveness.
  162. D2 Dopamine Receptor Binding in the Basal Ganglia of Antipsychotic-Free Schizophrenic Patients
  163. Dopamine D2 receptor occupancy in vivo and response to the new antipsychotic risperidone
  164. 99mTc-HMPAO single photon emission tomography in late life depression: a pilot study of regional cerebral blood flow at rest and during a verbal fluency task
  165. Antipsychotic medication, D2 dopamine receptor blockade and clinical response: a 123I IBZM SPET (single photon emission tomography) study
  166. Elevated frontal cerebral blood flow in Gilles de la Tourette syndrome: A 99Tcm-HMPAO SPECT study
  167. Assessment of myocardial viability with 201T1 SPET and reinjection technique
  168. Demonstration of human motor cortex activation using SPECT
  169. Effect of vigabatrin on striatal dopamine receptors: evidence in humans for interactions of GABA and dopamine systems.
  170. rCBF abnormalities detected, and sequentially followed, by SPECT in neuro-Behcet's syndrome with normal CT and MRI imaging
  171. Cerebral Blood Flow Abnormalities in Adults with Infantile Autism
  172. Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia
  173. Vasodilator myocardial perfusion imaging: demonstration of local electrophysiological changes of ischaemia
  174. Postviral fatigue syndrome.
  175. SPECT in epilepsy
  176. Physical assessment of the GE/CGR Neurocam and comparison with a single rotating gamma-camera
  177. Diagnosing Alzheimer's disease.
  178. Thallium Myocardial Perfusion Tomography in Clinical Cardiology
  179. Clinical Applications
  180. Clinical Case Material
  181. Image Interpretation
  182. Imaging Techniques
  183. Introduction
  184. Radiopharmaceuticals
  185. Stress Techniques
  186. The Future
  187. Endocardial monophasic action potential recordings for the detection of muocardial ischemia in man: A study using atrial pacing stress and myocardial perfusion scintigraphy
  188. Single photon emission tomography in Alzheimer's disease. A longitudinal study of changes in relative regional cerebral blood flow
  189. Single photon emission tomography in growth-hormone related Creutzfeldt-Jakob disease
  190. Diagnosis of brain death with technetium 99m hexamethylpropylene amine oxime
  191. The use of cerebral activation procedures with single photon emission tomography
  192. 99TCm-HMPAO SPECT studies in traumatic intracerebral haematoma.
  193. A Historical and Philosophical Review of Localizing Brain Function
  194. Activation Protocols in Normal Subjects Using SPET: A Window into Normal Brain Function
  195. Activation Studies in Specific Disease States: Future Applications
  196. Clinical Use of SPET Imaging in Psychiatric and Neurological Disease
  197. Description and Principles of Neuroactivation
  198. Models of Brain Processing with Respect to Functional Neuroimaging
  199. Neuroactivation and Neuroimaging with SPET
  200. Principles of Emission Tomography
  201. Radiopharmaceutical Ligands and Tracers
  202. Review of Previous SPET Neuroactivation Studies in Normal Controls
  203. SPET Instrumentation: Characteristics and New Developments
  204. The use of cerebral activation procedures with single photon emission tomography
  205. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans
  206. Single photon emission tomography (SPET) with 99Tc m-hexamethylpropyleneamineoxime (HMPAO) in research and clinical practice - a useful tool
  207. Regional cerebral blood flow (rCBF) during migraine using 99mTc-hexamethylpropyleneamineoxime (99mTc-HMPAO) and single photon emission tomography (SPET)
  208. 99Tcm-HMPAO SPET and cerebral blood flow
  209. Intracellular localization of 99Tcm-d, 1-HMPAO and 201T1-DDC in rat brain
  210. DIAGNOSIS OF HERPES SIMPLEX ENCEPHALITIS BY SINGLE PHOTON EMISSION TOMOGRAPHY
  211. ROLE OF ROUTINE FUNCTIONAL BRAIN IMAGING IN TEMPORAL LOBE EPILEPSY
  212. 99mTc-HMPAO WASHOUT FROM BRAIN
  213. Technetium-99m Pentavalent DMSA Imaging Detects Metastases of Poorly Differentiated Carcinoma of the Thyroid
  214. The investigation of Alzheimer's disease with single photon emission tomography.
  215. 99mTc-HMPAO WASHOUT IN PROGNOSIS OF STROKE
  216. White cells radiolabelled with 111IN AND 99Tcm- a study of relative sensitivity and in vivo viability
  217. RADIONUCLIDE IMAGING OF SCROTUM
  218. TRANSIENT LEUCOPENIA INDUCED BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
  219. IMAGING CEREBRAL DAMAGE IN HIV INFECTION
  220. Functional imaging of the brain
  221. Stress induced right ventricular dysfunction: An indication of reversible right ventricular ischaemia
  222. The in vivo distribution of 99Tcm-HM-PAO in normal man
  223. REGULAR CEREBRAL BLOOD FLOW MAPPING WITH 99mTc-LABELLED COMPOUND